Immunotherapy has revolutionized cancer treatment. Despite its success across various malignancies, a significant proportion of patients either fail to respond (primary resistance) or relapse after an initial response (acquired resistance). This review explores the different mechanisms underlying resistance to immunotherapy, including tumor-intrinsic factors such as loss of antigen presentation, genetic, and epigenetic mutations. It also examines tumor-extrinsic contributors, such as immunosuppressive cells in the tumor microenvironment, checkpoint molecule upregulation, and microbiome influences. A comprehensive understanding of resistance mechanisms is essential for improving patient selection, developing combination therapies, and ultimately enhancing the efficacy and durability of immunotherapeutic interventions.
Cancer Resistance to Immunotherapy
Rita Khoury,Annoir Shayya,Cendrella Bou Orm,Osama Zein Deen,Hady Ghanem
Published 2025 in Immuno
ABSTRACT
PUBLICATION RECORD
- Publication year
2025
- Venue
Immuno
- Publication date
2025-08-05
- Fields of study
Not labeled
- Identifiers
- External record
- Source metadata
Semantic Scholar
CITATION MAP
EXTRACTION MAP
CLAIMS
- No claims are published for this paper.
CONCEPTS
- No concepts are published for this paper.
REFERENCES
Showing 1-62 of 62 references · Page 1 of 1
CITED BY
Showing 1-2 of 2 citing papers · Page 1 of 1